Clover Health VP sells 20K shares at $5.16

Clover Health Investments (CLOV) reported that Joseph Frank Oldakowski, its VP of Finance and Controller, sold 20,000 shares of Class A Common Stock on September 14, 2026 at $5.16 per share in an open-market or private transaction.

Rhea-AI Filing Summary

Clover Health Investments (CLOV) reported that Joseph Frank Oldakowski, its VP of Finance and Controller, sold 20,000 shares of Class A Common Stock on September 14, 2026 at $5.16 per share in an open-market or private transaction. Following this sale, he continues to hold 279,067 shares directly.

Insider Trade Summary

Net Seller: 20,000 shares

Net Sell 1 txn

Insider OLDAKOWSKI JOSEPH FRANK

Role VP OF FINANCE AND CONTROLLER

Sold 20,000 shs ($103K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	20,000	$5.16	$103K

Holdings After Transaction: Class A Common Stock — 279,067 shares (Direct)

Key Figures

Shares sold: 20,000 shares Sale price per share: $5.16 per share Shares owned after transaction: 279,067 shares +1 more

4 metrics

Shares sold 20,000 shares Class A Common Stock sold on September 14, 2026

Sale price per share $5.16 per share Price for the 20,000 Class A shares sold

Shares owned after transaction 279,067 shares Direct holdings of VP of Finance and Controller after sale

Net buy/sell shares 20,000 shares net sold Net insider share change reported in this Form 4

Key Terms

Class A Common Stock, open market or private transaction, directly holds

3 terms

Class A Common Stock financial

"sold 20,000 shares of Class A Common Stock on September 14, 2026"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

open market or private transaction financial

"Sale in open market or private transaction"

directly holds financial

"he continues to hold 279,067 shares directly"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CLOV report in this Form 4?

Clover Health Investments reported that VP of Finance and Controller Joseph Frank Oldakowski sold 20,000 shares of Class A Common Stock on September 14, 2026 at $5.16 per share in an open-market or private transaction.

How many CLOV shares does the VP of Finance hold after the reported sale?

After the reported sale, VP of Finance and Controller Joseph Frank Oldakowski directly holds 279,067 shares of Clover Health Class A Common Stock, according to the Form 4 filing.

Was the CLOV insider trade made under a Rule 10b5-1 trading plan?

The Form 4 indicates that the Rule 10b5-1 checkbox is not affirmed, and there are no footnotes describing a trading plan, so no Rule 10b5-1 plan is reported for this transaction.

What was the price for the CLOV shares sold by the VP of Finance?

The 20,000 shares of Clover Health Class A Common Stock reported sold by the VP of Finance and Controller were transacted at a price of $5.16 per share, as disclosed in the Form 4.

Is the CLOV insider ownership reported as direct or indirect?

The Form 4 reports that the 279,067 shares of Clover Health Class A Common Stock held after the transaction are owned directly by VP of Finance and Controller Joseph Frank Oldakowski.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 08:53 PM Accepted by SEC EDGAR 09/14/2026 - 08:52 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

OLDAKOWSKI JOSEPH FRANK

(Last) (First) (Middle)

C/O CLOVER HEALTH INVESTMENTS, CORP.

(Street)

WILMINGTON DELAWARE 19801

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CLOVER HEALTH INVESTMENTS, CORP. /DE [ CLOV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP OF FINANCE AND CONTROLLER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	09/14/2026		S		20,000	D	$5.16	279,067	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Peter J. Rivas as attorney-in-fact for Joseph Frank Oldakowski	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)